GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Dai Han Pharm Co 023910.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

24,800

+0.40%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩208.61bn

FY2016FY2025

Net income

₩27.64bn

FY2016FY2025

Free cash flow

₩481.5m

FY2016FY2025

Shareholders' equity

₩300.21bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩208.61bn₩204.19bn₩195.91bn₩184.27bn₩171.46bn₩166.08bn₩168.76bn₩158.72bn₩144.44bn₩139.44bn
Gross profit₩64.82bn₩69.79bn₩74.59bn₩60.24bn₩67.45bn₩67.84bn₩59.50bn₩60.25bn₩54.79bn₩43.62bn
Research and development₩2.21bn₩1.80bn₩1.64bn₩567.9m₩790.6m₩689.2m₩392.4m₩458.1m₩382.3m₩410.2m
Operating income₩31.19bn₩38.03bn₩35.71bn₩33.56bn₩28.94bn₩29.96bn₩33.64bn₩36.22bn₩32.25bn₩21.72bn
Net income₩27.64bn₩33.76bn₩28.43bn₩24.96bn₩22.67bn₩17.38bn₩28.17bn₩28.52bn₩24.83bn₩17.66bn
Diluted earnings per share4,701.335,741.344,834.414,160.093,778.402,896.804,694.444,753.024,138.732,942.88

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩347.66bn₩324.41bn₩294.25bn₩276.98bn₩272.54bn₩253.09bn₩246.85bn₩234.75bn₩184.40bn₩160.31bn
Cash and short-term investments—₩77.24bn₩104.36bn₩97.61bn₩96.42bn₩67.60bn₩53.87bn₩42.53bn₩16.02bn₩12.26bn
Total liabilities₩47.45bn₩48.42bn₩46.28bn₩51.58bn₩69.73bn₩71.17bn₩80.08bn₩94.39bn₩68.52bn₩67.36bn
Debt—₩29.0m—₩6.50bn₩23.52bn₩28.76bn₩31.84bn₩38.40bn₩20.60bn₩14.60bn
Shareholders' equity₩300.21bn₩275.99bn₩247.97bn₩225.40bn₩202.81bn₩181.92bn₩166.78bn₩140.36bn₩115.88bn₩92.94bn
Shares outstanding6m6m6m6m6m6m6m6m6m6m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩25.60bn₩35.64bn₩38.86bn₩29.00bn₩40.62bn₩33.63bn₩35.26bn₩44.94bn₩20.45bn₩27.92bn
Capital spending−₩25.12bn−₩15.80bn−₩21.28bn−₩8.62bn−₩11.85bn−₩5.36bn−₩17.30bn−₩46.69bn−₩21.05bn−₩21.90bn
Free cash flow₩481.5m₩19.84bn₩17.58bn₩20.38bn₩28.77bn₩28.27bn₩17.96bn−₩1.75bn−₩592.2m₩6.03bn
Dividends paid−₩5.19bn−₩4.33bn−₩3.75bn−₩2.11bn−₩2.11bn−₩2.11bn−₩1.64bn−₩1.80bn−₩1.32bn−₩1.08bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩56.61bn₩52.71bn₩51.06bn₩56.17bn₩51.49bn₩49.89bn₩51.44bn₩54.85bn
Gross profit₩16.74bn₩15.84bn₩13.05bn₩18.49bn₩16.08bn₩17.20bn₩17.15bn₩18.74bn
Operating income₩8.08bn₩7.86bn₩3.57bn₩10.64bn₩7.75bn₩9.23bn₩8.69bn₩10.83bn
Net income₩6.75bn₩6.98bn₩5.08bn₩8.72bn₩6.20bn₩7.65bn₩8.99bn₩8.49bn
Diluted earnings per share1,148.461,187.22863.201,482.801,054.941,300.401,528.611,443.21
Cash from operations₩16.55bn₩8.09bn₩3.21bn₩9.47bn₩5.29bn₩7.63bn₩35.64bn₩11.49bn
Capital spending−₩3.86bn−₩1.76bn−₩748.0m−₩10.79bn−₩9.64bn−₩3.94bn−₩15.80bn−₩3.23bn
Free cash flow₩12.69bn₩6.33bn₩2.46bn−₩1.32bn−₩4.35bn₩3.69bn₩19.84bn₩8.25bn
Total assets₩359.26bn₩352.90bn₩347.66bn₩344.02bn₩334.95bn₩331.36bn₩324.41bn₩313.35bn
Cash and short-term investments—————₩107.01bn₩77.24bn₩73.89bn
Debt—————₩9.0m₩2.8m—
Shareholders' equity₩308.07bn₩301.16bn₩300.21bn₩293.27bn₩284.55bn₩278.35bn₩275.99bn₩268.33bn

Financial ratios

Data as of 6 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross margin31.1%34.2%38.1%32.7%39.3%40.8%———
Operating margin14.9%18.6%18.2%18.2%16.9%18.0%———
Net margin13.3%16.5%14.5%13.5%13.2%10.5%———
Return on equity9.2%12.2%11.5%11.1%11.2%9.6%———
Return on assets8.0%10.4%9.7%9.0%8.3%6.9%———
Free cash flow yield——————32.3%56.3%25.5%
Revenue growth2.2%4.2%6.3%7.5%3.2%-1.6%———
Earnings growth-18.1%18.8%13.9%10.1%30.4%-38.3%———
Current ratio3.64x3.22x3.87x3.65x3.20x3.10x———
Debt to equity—0.00x0.00x0.03x0.08x0.13x0.18x——
Equity ratio86.4%85.1%84.3%81.4%74.4%71.9%———
Interest coverage11601.75x21067.25x680.69x56.55x61.66x48.56x———
R&D as a share of sales1.1%0.9%0.8%0.3%0.5%0.4%———
Buybacks as a share of market value——————0.0%0.0%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.2%4.7%5.3%
Operating income-2.4%0.8%5.3%
Net income3.5%9.7%7.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin32.6%34.0%35.8%35.5%
Operating margin16.8%17.5%17.5%18.2%
Net margin14.9%14.5%13.7%14.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings6.24.65.77.47.611.46.78.19.99.5
Price to sales0.80.80.81.01.01.21.11.41.71.2

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2024.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year900.00750.00650.00400.00400.00400.00300.00300.00
  • 10-for-1 split · 29 Apr 2002

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.